ABSTRACT
INTRODUCTION
Obstructive sleep apnea (OSA) is defi ned as repetitive episodes of upper airway obstruction that occur during sleep, usually associated with a reduction in oxygen saturation [1] . Th e prevalence of OSA is found to be 4% in men and 2% in women, (male to female ration is 2:1) [1] . Th e severity of OSA is measured by apnea and hypopnea index (AHI), which is represented by the number of apnea and hypopnea events per hour of sleep. Th e gold standard treatment option for obstructive sleep apnea is continuous positive airway pressure (CPAP) [2] .
Psychiatric conditions were found to be more prevalent in individuals with OSA than those without the disease [3] . Life time prevalence of generalized anxiety disorder in general population is 5.7% [4] . In contrast, 18.5% of patients with sleep disordered breathing had anxiety in one study [5] . In a study conducted by Sharafk haneh et al., [3] the prevalence of anxiety among patients with OSA was reported to be 16.67% and depression was 21.75% [3] . More recently Mysliwiec et al., [6] reported a very high prevalence of anxiety in OSA patients reaching 47.5% (excluding post-traumatic stress disorder) [6] . Th ey also reported that the prevalence of depression in OSA patients was as high as 41.4%. Recently, in a community based study, the prevalence of OSA in patients with anxiety was found to be alarmingly as high as 57.1% [7] .
Although psychiatric problems were found to be more common among patients with OSA, their relationship to the severity of sleep apnea was inconsistent. Th ere was a weak but signifi cant association between apnea hypopnea index (AHI) and the presence of anxiety and depression [5] . On the other hand, severity of OSA which is represented by AHI did not show a signifi cant correlation with anxiety [8] . Interestingly, CPAP therapy for OSA showed signifi cant improvement of depression symptoms at short-term and long-term follow up periods [9] . Moreover, a systematic review demonstrated a moderate eff ect of positive airway pressure on depression and anxiety symptoms in patients with OSA [10] . Nevertheless, the prevalence of psychiatric problems among Saudis has not been studied before. In this study, we tried to address the prevalence of psychiatric problems such as depression, anxiety and stress among those with OSA and their relation to the severity of AHI. We also examined the prevalence of these conditions among patients on CPAP therapy.
MATERIAL AND METHODS

Study Design and Participants
All consecutive patients at risk of obstructive sleep apnea referred to the sleep clinic at King Abdulaziz University Hospital (KAUH), Jeddah, Kingdom of Saudi Arabia from January 2015 till February 2016 were recruited for this cross-sectional study. Th ose who already have confi rmed OSA were included. History of psychotic illnesses or use of antipsychotic medication in the last six months are the excluding criteria. Th e questionnaire was administered in the Arabic language. One English speaking patient used the original English version of the questionnaire.
Questionnaire Administration
Th e questionnaire was self-administered. Th ose with sight problems were interviewed by one of the investigators. Participants were informed about the confi dentiality of the study. Ethical approval was granted by the Research Ethics Committee at Faculty of Medicine, KAU.
Variables
Depression Anxiety Stress Scale (DASS) was used for data collection. It is a 42-item self-reported instrument designed to measure the severity of depression, anxiety and stress. It is a valid and reliable questionnaire for depression and anxiety assessment [11, 12] . A validated Arabic form was printed from this website: http://www2.psy.unsw.edu.au/ dass/. A score of 0-9 from depression scale is considered normal, 10-13 is mild, 14-20 is moderate, 21-27 is severe and 28 or more is a very severe depression. For anxiety, a score of 0-7 is normal, 8-9 is mild, 10-14 is moderate, 15-19 is severe and 20 or above is a very severe anxiety. Regarding stress, a score of 0-14 is normal, 15-18 is mild, 19-25 is moderate, 26-33 is severe, 34 or more is considered very severe stress.
Statistical Analysis
Th e Statistical Package for Social Sciences (IBM SPSS Statistics for Windows, Version 20, IBM Corp., Armonk, NY USA) was used. Data were presented as mean ± standard deviation or number (%) as appropriate. Comparison of the measured parametric parameters between groups was made using one-way analysis of variance (ANOVA) (LSD) test for normal distributed data. Mann-Whitney test was used for abnormal distributed data. Between non-parametric parameters, chi-square test was used. A probability (P) < 0.05 was considered signifi cant.
RESULTS
Seventy-fi ve patients with diff erent severity of obstructive sleep apnea were recruited (Table 1 ). Table 1 shows that there was insignifi cant diff erence in age and Epworth sleepiness scale (ESS) between patients with diff erent severity of OSA. Males participating in this study were insignifi cantly higher than females (65.3% versus 34.7%, P = 0.33). However, in severe OSA, males were signifi cantly higher than females (74.2% versus 25.8%, P = 0.007). Meanwhile, there was insignifi cant diff erence between the number of males and females in patients with mild (55.6% versus 44.4%, P = 0.567) and moderate OSA (64.7% versus 35.3%, P = 0.225). Th e BMI was signifi cantly higher in patients with severe versus moderate OSA (P = 0.015). Table 2 demonstrates the prevalence of depression, anxiety and stress (50%, 54.1% and 64%, respectively). Th is is very high if compared with the reported prevalence of depression (35.7%) [13] and anxiety (13.8%-17.4%) [14] Saudi Arabia. However, there is no population study in Saudi Arabia evaluating stress. In addition, the prevalence of depression and anxiety appears to be higher in patients with severe OSA (54.8%, P = 0.049 and 64.5%, P = 0.363, respectively) compared to those with moderate (52.9%, P = 0.181 and 41.2%, P = 0.015, respectively) and mild OSA (40.7%, P = 0.001 and 51.9%, P = 0.038, respectively). However, the prevalence of stress appeared to be the same among severe, moderate and mild OSA.
Th e study included 20 patients on CPAP and 55 patients off CPAP. Treatment duration, hours of CPAP use at night and compliance were not investigated in our study. Table 3 reveals that there is a signifi cant diff erence in the prevalence of depression, anxiety and stress in patients receiving CPAP treatment and those off treatment. Th e prevalence of depression in those on CPAP is 40%, while it is 52.7% in those off CPAP (P = 0.001). Moreover, those patients with anxiety and stress on CPAP accounted for 55% (n = 11) and 65% (n = 13) compared to untreated patients 54.5% (n = 30) and 65.5% (n = 36) (P = 0.003 and P = 0.001, respectively).
Th ere was a tendency towards having more patients with 3 disorders among patients with severe OSA compared with mild or moderate OSA (Table 4 ). Table 5 shows that the prevalence of two or three disorders was signifi cantly lower in the CPAP treated group than those off CPAP, (P = 0.008 and P = 0.011, respectively). Moreover, the prevalence of having no disorder (i.e., no depression, anxiety, or stress) was higher among patients on CPAP (P = 0.033). Th ere was no signifi cant diff erence between the two groups in regard to one disorder (P = 0.739).
Analysis of the polysomnography (PSG) revealed that there was no signifi cant diff erence in the percentage of rapid eye movement sleep (REM) (P = 0.965), stage 1 (P = 0.564), stage 2 (P = 0.492) and stage 3 (P = 0.468) between patients with and without depression. Similar results were obtained in regard to anxiety and stress (Table 6 ).
DISCUSSION
Fift y percent of our patients with OSA had depression ( Table 2) . Th e prevalence was higher among patients with severe OSA. In contrast, the prevalence of depression among the general population was reported in other studies to be much less. Th e life time prevalence of depression in the general population was found ranging between 8-12% [15] . On the other hand, studies from Saudi Arabia revealed that the prevalence of depression among the Saudi population was found to be 35.7% [13] , which is much less than the prevalence among OSA seen in this present study. However, other studies that evaluated the prevalence of depression in OSA patients showed variable results. Th e prevalence ranged between 5 to 63% [16] . Th ose studies used diff erent tools to diagnose depression, none of them used DASS. In a veteran's study that reviewed a database of more than 118,105 patients with OSA, they used the International Classifi cation of Diseases (ICD) coding system as a tool for data collection. Th ey found that 21.8% had depression [3] . Another study evaluated 284 patients with newly diagnosed 
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OSA. Mini International Neuropsychiatric Interview (MINI) administered by a trained psychologist was used in the evaluation. Depression prevalence in this study was 6% [17] . A study evaluated a smaller sample size (55 patients) using Zung Self-Rating Depression Scale (SDS). Th ey found that 45% of OSA patients had depression [18] . A Chinese study published in 2016 evaluated 1327 patients with OSA [19] . Using Self-Rating Depression Scale (SDS) revealed that 47.4% had depression. Th e variation in the prevalence of depression reported by diff erent studies can be attributed to the diff erent sample sizes, study population, age groups and the psychiatric assessment tools used. Nevertheless, it seems that the more recent studies with more objective evaluation of depression have a higher prevalence of depression among OSA. In addition, we found that depression correlated with severity of OSA. It was found to be more prevalent in severe OSA patients.
Similarly, anxiety and stress prevalence in our study population was found to be 56.6% and 65.3%, respectively (Table 2) . Th e previously mentioned veteran's study evaluated the prevalence of anxiety as well. Th ey found that the prevalence of anxiety in OSA patients was 16.7% [3] . A cross-sectional study evaluated 178 patients with OSA using Beck anxiety inventory (BAI) scoring. Th ey found that the prevalence of anxiety was 46.1% [20] . Although they found that the severity of OSA correlated with anxiety and depression, a larger study included 658 recently diagnosed OSA patients found that there is no association between severity of OSA and depression or anxiety [21] . Th is discrepancy could be explained by diff erence in study design and size. Moreover, our study showed no correlation between the prevalence of anxiety and stress and the severity of OSA.
Povitz et al., [22] published a meta-analysis in 2014 about the eff ect of CPAP on depression symptoms in OSA patients. Th ey found that CPAP improved depression with signifi cant heterogenicity. Table 3 presents the diff erence in prevalence of depression, anxiety and stress in patients on CPAP and those who have never been treated. It shows that the prevalence of depression, anxiety and stress was signifi cantly lower in those who are on CPAP. In addition, the prevalence of severe and very severe depression and anxiety was non-signifi cant between the two groups while severe and very severe stress prevalence was lower among CPAP group. A small study evaluated patients with OSA aft er six months on CPAP. Th ey found that anxiety scores were signifi cantly decreased with treatment [23] . Moreover, CPAP therapy was found to have a positive eff ect on job productivity and occupational well-being in patients with severe OSA. However, it did not decrease job stress or job dissatisfaction [24] . Th erefore, patients with psychiatric disorders who have features of sleep apnea should be screened fi rst for OSA, since instituting CPAP might be a reasonable treatment option in dealing with psychiatric disorders associated with OSA.
Polysomnography evaluation of patients with depression showed an increase in sleep latency, frequent awakening, decrease in slow wave sleep (Stage III) and increase in REM percentage [25] . Sleep architecture in our study did not show any signifi cant diff erence between OSA patients with or without depression, anxiety or stress (Table 6 ). It was found that 45% of depressed patients may show PSG changes in outpatient settings, and 80% in inpatient settings [26] . Evaluation of sleep architecture was not consistent in our study. It was evaluated from a full night sleep study in some patients. However, some patients were evaluated using their split night study or a titration study. Moreover, our fi ndings were not adjusted for age and sex. In addition, studies that showed a signifi cant diff erence between OSA patients with depression and those without any psychiatric illness had a relatively larger sample size [27] .
Our study suff ers from some last level limitations, including the small size and the cohort of the patients used. In addition, OSA symptoms may overlap with depression and anxiety symptoms, which makes the evaluation of these psychiatric disorders in OSA diffi cult. A recently published study evaluated the use of DASS-21 scale, which is a shorter version than we used in our study, in untreated OSA [28] . It found that despite overlap symptoms between OSA, depression and anxiety, which can increase the score, DASS-21 can be considered as a suitable tool to assess depression and anxiety in OSA. Another limitation of our study is the lack of objective assessment of CPAP therapy i.e., compliance and duration of treatment. Th is may aff ect our observation regarding the eff ects of CPAP on psychiatric disorders in patients with OSA.
In summary, our study revealed that mood disorders are very common among patients with OSA and their prevalence tends to increase with the severity of obstructive sleep apnea and decrease among those receiving continuous positive airway pressure. Hence, physicians should consider comorbidities such as OSA when evaluating a patient with mood disorders.
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